Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting the epitranscriptomics machinery.
By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.
LEE BABISS, CEO
Unprecedented targets that play a key role in mRNA biology and our efforts will reveal a novel drug class targeting the epitranscriptomics machinery…
… and opening the door to now address diseases that are currently underserved. Read more about LEE >
GERHARD MUELLER, CSO
Gotham will focus initially on targets with the most compelling links to disease…
… and move on rapidly to develop small molecule inhibitors employing diverse screening strategies coupled with state-of-the art medicinal chemistry. Read more about GERHARD >
BIRGIT ZECH, COO
As the pharmaceutical industry opens up to the reality of RNA modification…
… we are seeing more companies moving into the field of epitranscriptomics as a way to address human diseases in a novel way. Read more about BIRGIT >
From #NYC to #MUC
Gotham is part of New York City’s rapidly growing biopharma community with a subsidiary in one of Europe’s leading life science clusters near Munich, Germany.
With the ability to attract talent on both sides of the Atlantic and recruit from two of the most vibrant academic talent pools in our industry, Gotham will complement its team of experts to spearhead target validation, drug discovery and development in the epitranscriptomics sector.
October 10, 2018 – Gotham Therapeutics Launches with $54 Million Series A
In October 2018, Gotham Therapeutics debuted with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One.